OrganiGram Holdings Inc.
TSX:OGI.TODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $135.37M
- Beta
- 1.84
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$0.19
Volume 0.54M
Average 0.19M
OGI.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
OrganiGram Holdings Inc.TSX: OGI.TO
Research & Development · Q2 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of CA$2.03M fell 23.9% year over year, behind the +9.4% change in trailing-twelve-month research & development. Sequentially, it fell 2.8% from the prior quarter.
Context
- Research & development amounted to 4.2% of revenue in FY2025, down 2.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -23.9% toward the trailing-twelve-month pace of +9.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 10.95M CAD
- Year-over-year change
- -2.3%
- 4-year CAGR
- +33.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 10.95M | -2.3% |
| FY2024 | 2024-09-30 | 11.2M | -8.1% |
| FY2023 | 2023-09-30 | 12.19M | +104.4% |
| FY2022 | 2022-08-31 | 5.96M | +72.8% |
| FY2021 | 2021-08-31 | 3.45M | — |
Research & Development vs competitors
How OGI.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.4% is the 4th highest of 6, against a peer median of +31.9%.
- Research & development amounts to 3.7% of revenue for OGI.TO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $27.07M USD | +139.8% | +7.0% | — | |
| LTM Mar 2026 | CA$10.02M CAD | +9.4% | — | 3.7% | |
| LTM Mar 2026 | CA$4.85M CAD | +31.9% | -15.1% | 1.5% | |
| LTM Mar 2026 | CA$267K CAD | +62.8% | — | 0.2% | |
| LTM Mar 2026 | $205.18K USD | -48.4% | -58.4% | 0.4% | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | -39.8% | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding OGI.TO) | — | +31.9% | -27.4% | 0.0% | |
Competitors are the stored peer set for OGI.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Aug 2021 | FY2022 Aug 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 79.16M | 145.81M | 149.21M | 159.84M | 259.18M |
| Cost of Revenue | 107.56M | 114.24M | 114.13M | 112.32M | 249.67M |
| Gross Profit | (28.4M) | 31.57M | 35.07M | 47.52M | 9.51M |
| Gross Margin | -35.9% | 21.7% | 23.5% | 29.7% | 3.7% |
| Research & Development | 3.45M | 5.96M | 12.19M | 11.2M | 10.95M |
| Selling, General & Admin | 46.52M | 59.21M | 71.68M | 68.14M | 86.88M |
| Operating Expenses | 63.42M | 70.32M | 277.81M | 83.2M | 97.82M |
| Depreciation & Amortization | 31.03M | 24.91M | 24.17M | 12.08M | 17.98M |
| EBITDA | (95.59M) | 10.97M | (207.62M) | (23.59M) | (20.55M) |
| EBITDA Margin | -120.8% | 7.5% | -139.2% | -14.8% | -7.9% |
| Operating Income | (91.82M) | (43.15M) | (242.74M) | (35.67M) | (88.31M) |
| Operating Margin | -116.0% | -29.6% | -162.7% | -22.3% | -34.1% |
| Interest Income | 0 | 0 | 3.69M | 3.31M | 1.15M |
| Interest Expense | 2.96M | 429K | 277.85K | 0 | 0 |
| Other Income / Expenses | (38.88M) | 28.78M | 9.74M | (9.77M) | 49.78M |
| Income Before Tax | (130.7M) | (14.37M) | (233M) | (45.44M) | (38.53M) |
| Pre-Tax Margin | -165.1% | -9.9% | -156.2% | -28.4% | -14.9% |
| Income Tax Expense | 0 | (88K) | (3.52M) | (5.28M) | (13.77M) |
| Net Income | (130.7M) | (14.28M) | (229.48M) | (45.44M) | (24.76M) |
| Net Margin | -165.1% | -9.8% | -153.8% | -28.4% | -9.6% |
| EPS (Basic) | (2.04) | (0.18) | (2.82) | (0.48) | (0.19) |
| EPS (Diluted) | (2.04) | (0.18) | (2.82) | (0.48) | (0.19) |
| Weighted Avg Shares | 64.03M | 77.23M | 81.29M | 95.29M | 127.67M |
| Weighted Avg Shares (Diluted) | 64.03M | 77.23M | 81.29M | 95.29M | 127.67M |
OrganiGram Holdings Inc.
TSX:OGI.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.